Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 3/20 | 0.51 |
| ▸ | CHRM5 | P08912 | 8/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 7/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2019500 | 0.88 | GRM2 (0.54) | GRM2CHRM5PIK3CGALOX5APGRIN2B | |
| SCHEMBL1003029 | 0.86 | GRM2 (0.52) | GRM2CHRM5PIK3CGGRIN2B | |
| SCHEMBL2019548 | 0.86 | GRM2 (0.53) | GRM2CHRM5PIK3CGALOX5APGRIN2B | |
| SCHEMBL2028802 | 0.85 | GRM2 (0.57) | GRM2CHRM5PIK3CGGRIN2B | |
| SCHEMBL2023362 | 0.85 | GRM2 (0.57) | GRM2CHRM5PIK3CGGRIN2B | |
| SCHEMBL1001737 | 0.85 | GRM2 (0.57) | GRM2CHRM5PIK3CG | |
| SCHEMBL2027874 | 0.84 | GRM2 (0.56) | GRM2CHRM5PIK3CGGRIN2B | |
| SCHEMBL2021690 | 0.83 | GRM2 (0.58) | GRM2CHRM5PIK3CG | |
| SCHEMBL2024652 | 0.82 | GRM2 (0.54) | GRM2CHRM5PIK3CGGRIN2B | |
| SCHEMBL2023271 | 0.80 | GRM2 (0.54) | GRM2CHRM5PIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2357169-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | AstraZeneca AB (SE) | 2011-08-17 | — | — | EP | disclosed |
| EP-2357169-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | AstraZeneca AB (SE) | 2011-08-17 | — | — | EP | disclosed |
| US-7968570-B2 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2011-06-28 | — | — | US | disclosed |
| US-7968570-B2 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2011-06-28 | — | — | US | disclosed |
| US-7968570-B2 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2011-06-28 | — | — | US | disclosed |
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | GRM1, GRIN1, GRM3 | GRM2 4/4885CHRM5 65/4885PIK3CG 1735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.